Buffalo, NEW%20YORK10 Active Studies

Leukemia Clinical Trials in Buffalo, NEW%20YORK

Find 10 actively recruiting leukemia clinical trials in Buffalo, NEW%20YORK. Connect with local research sites and explore new treatment options.

10
Active Trials
10
Sponsors
1,825
Enrolling

Recruiting Leukemia Studies in Buffalo

RecruitingBuffalo, NEW%20YORKNCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

600 participants
Janssen Research & Development, LLC
View Study Details
RecruitingBuffalo, NEW%20YORKNCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

242 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBuffalo, NEW%20YORKNCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

236 participants
Taiho Oncology, Inc.
View Study Details
RecruitingBuffalo, NEW%20YORKNCT04471727

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig w...

232 participants
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
View Study Details
RecruitingBuffalo, NEW%20YORKNCT06969430

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

134 participants
Debiopharm International SA
View Study Details
RecruitingBuffalo, NEW%20YORKNCT06824168

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...

130 participants
Daiichi Sankyo
View Study Details
RecruitingBuffalo, NEW%20YORKNCT05143840

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...

100 participants
Augusta University
View Study Details
RecruitingBuffalo, NEW%20YORKNCT05442216

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

53 participants
Joshua Zeidner
View Study Details
RecruitingBuffalo, NEW%20YORKNCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

52 participants
Cellectis S.A.
View Study Details
RecruitingBuffalo, NEW%20YORKNCT04269213

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs u...

46 participants
Roswell Park Cancer Institute
View Study Details

About Leukemia Clinical Trials in Buffalo

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 10 leukemia clinical trials recruiting participants in Buffalo, NEW%20YORK. These studies are seeking a combined 1,825 participants. Research is being sponsored by Janssen Research & Development, LLC, Merck Sharp & Dohme LLC, Taiho Oncology, Inc. and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Buffalo — FAQ

Are there leukemia clinical trials in Buffalo?

Yes, there are 10 leukemia clinical trials currently recruiting in Buffalo, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Buffalo?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.

Are clinical trials in Buffalo free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 10 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated March 2, 2026 from ClinicalTrials.gov